AMAG Pharma (AMAG): Low Expectations Shift The Risk Reward To The Upside - Jefferies
- AT&T (T) Agrees to Acquire Time Warner (TWX) for More than $80 Billion - WSJ
- Top 10 News for 10/17 - 10/21: Merger Rumors Abound; CEOs Depart; Tesla Kicks Autopilot Up A Notch
- Wall Street ends little changed; Microsoft hits record
- AT&T (T) in Advanced Talks to Acquire Time Warner (TWX) - DJ
- Rockwell Automation (ROK) Said to Attract Takeover Interest from Schneider Electric - Source
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Jefferies analyst, Eun Yang, reiterated her Buy rating on shares of AMAG Pharmaceuticals (NASDAQ: AMAG) noting that the Makena franchise (~60% of current revenue) has been disappointing since 3Q15 on missed sales/delays in line-extension strategies. The current share price abundantly reflects such frustration and assumes that Makena & Feraheme sales are going to zero following 02/18 & 06/23 exclusivity expiry. That may turn out to be the case or it may take a while for AMAG to regain investors' confidence but the analyst thinks that the risk/reward seems skewed to the upside .
The price target drops to $45.00 from $58.00 but reflects substantial upside from the current price of $25.51.
Shares of AMAG Pharmaceuticals closed at $22.31 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Maxim Integrated (MXIM) PT Bumped to $45 at Jefferies Following In-Line Results on Note 7 Impact
- SunTrust Raises Price Target on E*TRADE Financial (ETFC) to $31 Following Solid 3Q
- Wedbush Reiterates Outperform on Pool Corp. (POOL) Following 3Q Report
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!